Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Over-the-counter HIV testing in NEJM

This article was originally published in The Gray Sheet

Executive Summary

Ingrid Katz, MD, and Alexi Wright, MD, Brigham and Women's Hospital, Boston, support the prospect of OraSure gaining over-the-counter approval for its OraQuick Advance rapid oral HIV test. In a perspective piece in the Feb. 2 issue of the New England Journal of Medicine, the authors acknowledge concerns, including test affordability and the recent reports of increased numbers of false positive results at certain clinics, but they say a low number of false positives is less dangerous than people incorrectly assuming they do not have HIV. After attending an FDA advisory panel meeting in November that discussed whether HIV tests should be available for over-the-counter use, both authors feel confident that the product will be approved once these issues are ironed out, they said in an interview (1"The Gray Sheet" Jan. 2, 2006, p. 23)....

You may also be interested in...



OraSure Studying “Site-Specific Factors” Behind Flawed HIV Test Results

OraSure is conducting an investigation of its OraQuick Advance rapid oral HIV test due to concerns about the test's reliability, the company said Dec. 20

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel